tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

PYXS Stock Latest News

3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
Market News3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
25d ago
PYXS
RGNX
Pyxis Oncology price target lowered to $5 from $8 at RBC Capital
PremiumThe Fly
Pyxis Oncology price target lowered to $5 from $8 at RBC Capital
28d ago
PYXS
Maintaining a Buy on Pyxis: Early MICVO Efficacy, Dose Optimization, and 2026 Data as the Next Major Catalyst
PremiumRatings
Maintaining a Buy on Pyxis: Early MICVO Efficacy, Dose Optimization, and 2026 Data as the Next Major Catalyst
28d ago
PYXS
Pyxis Oncology price target raised to $7 from $5 at H.C. Wainwright
PremiumThe Fly
Pyxis Oncology price target raised to $7 from $5 at H.C. Wainwright
28d ago
PYXS
Pyxis Oncology Reports Strong MICVO Data and Financing
PremiumCompany Announcements
Pyxis Oncology Reports Strong MICVO Data and Financing
29d ago
8K
PYXS
Pyxis Oncology announces preliminary Phase 1 data for micvotabart pelidotin
PremiumThe FlyPyxis Oncology announces preliminary Phase 1 data for micvotabart pelidotin
29d ago
MRK
PYXS
Pyxis to present updated data from Phase 1 monotherapy study in mid-2026
Premium
The Fly
Pyxis to present updated data from Phase 1 monotherapy study in mid-2026
29d ago
PYXS
Pyxis Oncology sees cash runway into 4Q26
Premium
The Fly
Pyxis Oncology sees cash runway into 4Q26
29d ago
PYXS
Pyxis Oncology files $350M mixed securities shelf
PremiumThe Fly
Pyxis Oncology files $350M mixed securities shelf
2M ago
PYXS
Pyxis Oncology price target raised to $8 from $5 at Stephens
PremiumThe Fly
Pyxis Oncology price target raised to $8 from $5 at Stephens
2M ago
PYXS
Pyxis Oncology Reports Increased Losses Amid Development Focus
PremiumCompany Announcements
Pyxis Oncology Reports Increased Losses Amid Development Focus
2M ago
PYXS
Promising Efficacy of Pyxis Oncology’s MICVO in HNSCC Justifies Buy Rating Despite Financial Constraints
PremiumRatings
Promising Efficacy of Pyxis Oncology’s MICVO in HNSCC Justifies Buy Rating Despite Financial Constraints
2M ago
PYXS
Buy Rating for Pyxis Oncology: Promising Clinical Data and Strong Financial Position
PremiumRatingsBuy Rating for Pyxis Oncology: Promising Clinical Data and Strong Financial Position
2M ago
PYXS
Promising Developments in Pyxis Oncology’s MICVO Drive Buy Rating
Premium
Ratings
Promising Developments in Pyxis Oncology’s MICVO Drive Buy Rating
2M ago
PYXS
Pyxis Oncology reports Q3 EPS (35c), consensus (34c)
Premium
The Fly
Pyxis Oncology reports Q3 EPS (35c), consensus (34c)
2M ago
PYXS
Pyxis Oncology resumed with a Buy at Stifel
PremiumThe Fly
Pyxis Oncology resumed with a Buy at Stifel
2M ago
PYXS
Pyxis Oncology’s Promising Study on PYX-201 and Pembrolizumab in Advanced Solid Tumors
PremiumCompany Announcements
Pyxis Oncology’s Promising Study on PYX-201 and Pembrolizumab in Advanced Solid Tumors
3M ago
PYXS
Pyxis Oncology’s PYX-201 Study: A Promising Step in Solid Tumor Treatment
PremiumCompany Announcements
Pyxis Oncology’s PYX-201 Study: A Promising Step in Solid Tumor Treatment
3M ago
PYXS
Pyxis Oncology appoints Alex Kane as SVP, IR, capital markets
PremiumThe Fly
Pyxis Oncology appoints Alex Kane as SVP, IR, capital markets
3M ago
PYXS
Pyxis Oncology initiated with a Buy at Guggenheim
PremiumThe FlyPyxis Oncology initiated with a Buy at Guggenheim
4M ago
PYXS
Pyxis Oncology initiated with a Buy at Guggenheim
Premium
The Fly
Pyxis Oncology initiated with a Buy at Guggenheim
4M ago
PYXS
Optimistic Buy Rating for Pyxis Oncology Driven by Promising MICVO Developments and Strategic Merck Collaboration
Premium
Ratings
Optimistic Buy Rating for Pyxis Oncology Driven by Promising MICVO Developments and Strategic Merck Collaboration
5M ago
PYXS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >